Metabolic dysfunction–associated steatotic liver disease and obstructive sleep apnea: A cohort analysis of prevalence and hepatic outcomes

Table 3 Primary outcomes comparing patients with metabolic dysfunction-associated steatotic liver disease and with and without obstructive sleep apnea after propensity score matching

Cohort for primary outcomes	MASLD with OSA, n = 364283	MASLD without OSA, n = 364283	Odds ratio (95%CI)	P value
Hepatic fibrosis
1 year	1895	1069	1.777 (1.648-1.915)	< 0.0001
3 years	2796	1384	2.028 (1.901-2.163)	< 0.0001
5 years	3243	1544	2.110 (1.986-2.243)	< 0.0001
10 years	3675	1740	2.123 (2.005-2.248)	< 0.0001
Hepatic cirrhosis
1 year	2914	1911	1.529 (1.443-1.620)	< 0.0001
3 years	4158	2716	1.537 (1.464-1.514)	< 0.0001
5 years	4822	3149	1.538 (1.471-1.609)	< 0.0001
10 years	5506	3620	1.529 (1.466-1.595)	< 0.0001

Incidence of hepatic fibrosis and hepatic cirrhosis at the 1-year, 3-year, 5-year, and 10-year follow-up among propensity score-matched cohorts with metabolic dysfunction-associated steatotic liver disease with and without obstructive sleep apnea. Outcomes are presented as event counts and corresponding odds ratios with 95%CIs. All analyses reflect matched sample sizes of 364283 per group. Logistic regression models were used to calculate odds ratios at each time point. MASLD: Metabolic dysfunction-associated steatotic liver disease; OSA: Obstructive sleep apnea.